Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Alcohol use disorder (AUD) is a significant global health burden.
• Chronic alcohol consumption leads to neuroplastic changes, excessive drinking, and cognitive impairments.
• The norepinephrine (NE) system, particularly the α2 adrenergic receptor (AR) subtype, is implicated in cognition and behavior.

Purpose of the Study:

• To investigate the effects of α2 AR activation on alcohol consumption and cognitive performance in mouse models.
• To determine if α2 AR agonists can mitigate the negative effects of heavy alcohol drinking.

Main Methods:

• Administration of α2 AR agonists (clonidine and guanfacine) to mice with varying levels of alcohol experience.
• Assessment of hypothermia, sedation, and ethanol consumption.
• Evaluation of cognitive function using behavioral tests (temporal order, novel object recognition, novel spatial location).
• Analysis of norepinephrine neuron activation in the locus coeruleus and nucleus of the tractus solitarius.

Main Results:

• Guanfacine, a selective α2 AR agonist, reduced heavy alcohol drinking in male and female mice with higher potency than clonidine.
• Guanfacine improved cognitive performance in some tests but not others in ethanol-experienced mice.
• Clonidine exacerbated alcohol-induced hypothermia and sedation.
• Chronic alcohol consumption increased persistent activation of NE neurons.

Conclusions:

• The α2 AR system plays a crucial role in regulating heavy alcohol consumption and associated cognitive deficits.
• Guanfacine shows promise as a pharmacological strategy for treating AUD due to its ability to reduce drinking and improve cognition.
• Targeting the norepinephrine system via α2 AR stimulation may be a viable therapeutic approach for AUD.